Financhill
Buy
55

RHHBY Quote, Financials, Valuation and Earnings

Last price:
$43.26
Seasonality move :
3.34%
Day range:
$42.52 - $43.32
52-week range:
$29.20 - $43.96
Dividend yield:
3.12%
P/E ratio:
30.14x
P/S ratio:
3.96x
P/B ratio:
7.83x
Volume:
8.1M
Avg. volume:
3.7M
1-year change:
31.53%
Market cap:
$275.3B
Revenue:
$70.9B
EPS (TTM):
$1.44

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RHHBY
Roche Holding AG
$16.9B -- -- -- $46.29
AZN
AstraZeneca PLC
$14.2B $1.04 8.37% 57.32% $85.10
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,006.63
NVO
Novo Nordisk AS
$11.5B $0.80 23.24% 6.35% $112.90
NVS
Novartis AG
$12.8B $1.76 6.82% 57% $108.96
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RHHBY
Roche Holding AG
$43.26 $46.29 $275.3B 30.14x $1.35 3.12% 3.96x
AZN
AstraZeneca PLC
$77.60 $85.10 $240.6B 34.41x $1.05 2% 4.48x
LLY
Eli Lilly and
$813.48 $1,006.63 $730.6B 69.47x $1.50 0.66% 16.33x
NVO
Novo Nordisk AS
$77.15 $112.90 $342.5B 23.50x $0.52 1.88% 8.18x
NVS
Novartis AG
$109.06 $108.96 $215.4B 18.55x $3.87 3.55% 4.29x
PFE
Pfizer
$25.72 $31.32 $145.8B 18.24x $0.43 6.57% 2.30x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RHHBY
Roche Holding AG
52.17% 0.691 16.91% 1.19x
AZN
AstraZeneca PLC
41.27% -0.475 -- 0.74x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
NVO
Novo Nordisk AS
40.09% 0.871 3.51% 0.52x
NVS
Novartis AG
40.07% 0.604 15.32% 0.80x
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RHHBY
Roche Holding AG
-- -- 12.15% 23.8% -- --
AZN
AstraZeneca PLC
$12.2B $2B 9.88% 17.77% 14.07% $2B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
NVO
Novo Nordisk AS
$10.4B $5.2B 60.28% 86.85% 40.78% -$786.4M
NVS
Novartis AG
$10.2B $3.5B 16.91% 27.64% 26.26% $3.1B
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B

Roche Holding AG vs. Competitors

  • Which has Higher Returns RHHBY or AZN?

    AstraZeneca PLC has a net margin of -- compared to Roche Holding AG's net margin of 10.07%. Roche Holding AG's return on equity of 23.8% beat AstraZeneca PLC's return on equity of 17.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    AZN
    AstraZeneca PLC
    81.7% $0.48 $69.5B
  • What do Analysts Say About RHHBY or AZN?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 7%. On the other hand AstraZeneca PLC has an analysts' consensus of $85.10 which suggests that it could grow by 9.67%. Given that AstraZeneca PLC has higher upside potential than Roche Holding AG, analysts believe AstraZeneca PLC is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    AZN
    AstraZeneca PLC
    6 2 0
  • Is RHHBY or AZN More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.758%.

  • Which is a Better Dividend Stock RHHBY or AZN?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.12%. AstraZeneca PLC offers a yield of 2% to investors and pays a quarterly dividend of $1.05 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or AZN?

    Roche Holding AG quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. Roche Holding AG's net income of -- is lower than AstraZeneca PLC's net income of $1.5B. Notably, Roche Holding AG's price-to-earnings ratio is 30.14x while AstraZeneca PLC's PE ratio is 34.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.96x versus 4.48x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    3.96x 30.14x -- --
    AZN
    AstraZeneca PLC
    4.48x 34.41x $14.9B $1.5B
  • Which has Higher Returns RHHBY or LLY?

    Eli Lilly and has a net margin of -- compared to Roche Holding AG's net margin of 32.59%. Roche Holding AG's return on equity of 23.8% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About RHHBY or LLY?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 7%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Roche Holding AG, analysts believe Eli Lilly and is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    LLY
    Eli Lilly and
    16 4 0
  • Is RHHBY or LLY More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock RHHBY or LLY?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.12%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or LLY?

    Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Roche Holding AG's net income of -- is lower than Eli Lilly and's net income of $4.4B. Notably, Roche Holding AG's price-to-earnings ratio is 30.14x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.96x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    3.96x 30.14x -- --
    LLY
    Eli Lilly and
    16.33x 69.47x $13.5B $4.4B
  • Which has Higher Returns RHHBY or NVO?

    Novo Nordisk AS has a net margin of -- compared to Roche Holding AG's net margin of 32.95%. Roche Holding AG's return on equity of 23.8% beat Novo Nordisk AS's return on equity of 86.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    NVO
    Novo Nordisk AS
    84.8% $0.91 $33.4B
  • What do Analysts Say About RHHBY or NVO?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 7%. On the other hand Novo Nordisk AS has an analysts' consensus of $112.90 which suggests that it could grow by 48.19%. Given that Novo Nordisk AS has higher upside potential than Roche Holding AG, analysts believe Novo Nordisk AS is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is RHHBY or NVO More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.420, suggesting its less volatile than the S&P 500 by 58.038%.

  • Which is a Better Dividend Stock RHHBY or NVO?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.12%. Novo Nordisk AS offers a yield of 1.88% to investors and pays a quarterly dividend of $0.52 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or NVO?

    Roche Holding AG quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $12.2B. Roche Holding AG's net income of -- is lower than Novo Nordisk AS's net income of $4B. Notably, Roche Holding AG's price-to-earnings ratio is 30.14x while Novo Nordisk AS's PE ratio is 23.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.96x versus 8.18x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    3.96x 30.14x -- --
    NVO
    Novo Nordisk AS
    8.18x 23.50x $12.2B $4B
  • Which has Higher Returns RHHBY or NVS?

    Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 20.79%. Roche Holding AG's return on equity of 23.8% beat Novartis AG's return on equity of 27.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    NVS
    Novartis AG
    75.48% $1.41 $73.6B
  • What do Analysts Say About RHHBY or NVS?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 7%. On the other hand Novartis AG has an analysts' consensus of $108.96 which suggests that it could fall by -0.09%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    NVS
    Novartis AG
    0 9 2
  • Is RHHBY or NVS More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.99%.

  • Which is a Better Dividend Stock RHHBY or NVS?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.12%. Novartis AG offers a yield of 3.55% to investors and pays a quarterly dividend of $3.87 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RHHBY or NVS?

    Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.8B. Notably, Roche Holding AG's price-to-earnings ratio is 30.14x while Novartis AG's PE ratio is 18.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.96x versus 4.29x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    3.96x 30.14x -- --
    NVS
    Novartis AG
    4.29x 18.55x $13.6B $2.8B
  • Which has Higher Returns RHHBY or PFE?

    Pfizer has a net margin of -- compared to Roche Holding AG's net margin of 2.31%. Roche Holding AG's return on equity of 23.8% beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    RHHBY
    Roche Holding AG
    -- -- $78.4B
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About RHHBY or PFE?

    Roche Holding AG has a consensus price target of $46.29, signalling upside risk potential of 7%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Pfizer has higher upside potential than Roche Holding AG, analysts believe Pfizer is more attractive than Roche Holding AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    RHHBY
    Roche Holding AG
    3 4 0
    PFE
    Pfizer
    6 13 1
  • Is RHHBY or PFE More Risky?

    Roche Holding AG has a beta of 0.404, which suggesting that the stock is 59.628% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock RHHBY or PFE?

    Roche Holding AG has a quarterly dividend of $1.35 per share corresponding to a yield of 3.12%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

  • Which has Better Financial Ratios RHHBY or PFE?

    Roche Holding AG quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Roche Holding AG's net income of -- is lower than Pfizer's net income of $410M. Notably, Roche Holding AG's price-to-earnings ratio is 30.14x while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.96x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RHHBY
    Roche Holding AG
    3.96x 30.14x -- --
    PFE
    Pfizer
    2.30x 18.24x $17.8B $410M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock